You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 6, 2024

Claims for Patent: 10,441,543

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,441,543

Title:	Processes for making cyclic lipid implants for intraocular use
Abstract:	Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
Inventor(s):	Spada; Lon T. (Walnut, CA), Chang; James N. (Newport Beach, CA), Luu; Michelle H. (Anaheim, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	14/876,436
Patent Claims:	1. A solid intraocular implant comprising a cyclic lipid therapeutic agent, a polymer and a low melting cosolvent, wherein the solubility parameters of the cyclic lipid therapeutic agent, the polymer and the low melting cosolvent are all within about 10 MPa.sup.1/2 of each other; wherein the low melting cosolvent has a melt temperature of between about 50.degree. C. and about 80.degree. C.; wherein the cyclic lipid therapeutic agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, prostaglandin E1, prostaglandin E2, and mixtures thereof; wherein the polymer is a biodegradable polymer selected from the group consisting of polylactic acid, polyglycolic acid, and polylactide-co-glycolide; and wherein the low melting cosolvent is selected from the group consisting of decafluorobutane, poly(hexamethylene adipamide), and polyethylene glycol 3350; wherein the cyclic lipid agent comprises 20% by weight of the intraocular implant, wherein the potency of the cyclic lipid therapeutic agent released from the implant is at least about 50% of its maximum potency; and wherein no polymorphs of the therapeutic agent are present in the implant. 2. The intraocular implant of claim 1, wherein the cyclic lipid therapeutic agent is bimatoprost. 3. The intraocular implant of claim 1, wherein the cyclic lipid therapeutic agent is latanoprost. 4. The intraocular implant of claim 1, wherein the cyclic lipid agent is travoprost. 5. The intraocular implant of claim 2, wherein the low melting cosolvent is polyethylene glycol 3350. 6. The intraocular implant of claim 1, wherein the implant is monolithic.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.